INNATE PHARMA SA (IDD.DE) Fundamental Analysis & Valuation

FRA:IDD • FR0010331421

Current stock price

1.086 EUR
-0.42 (-27.89%)
Last:

This IDD.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. IDD.DE Profitability Analysis

1.1 Basic Checks

  • In the past year IDD has reported negative net income.
  • In the past year IDD has reported a negative cash flow from operations.
  • IDD had negative earnings in each of the past 5 years.
  • In the past 5 years IDD always reported negative operating cash flow.
IDD.DE Yearly Net Income VS EBIT VS OCF VS FCFIDD.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

  • With a Return On Assets value of -49.55%, IDD is not doing good in the industry: 63.29% of the companies in the same industry are doing better.
  • Looking at the Return On Equity, with a value of -895.24%, IDD is doing worse than 67.09% of the companies in the same industry.
Industry RankSector Rank
ROA -49.55%
ROE -895.24%
ROIC N/A
ROA(3y)-25.54%
ROA(5y)-23.43%
ROE(3y)-227.3%
ROE(5y)-154.41%
ROIC(3y)N/A
ROIC(5y)N/A
IDD.DE Yearly ROA, ROE, ROICIDD.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400 -500

1.3 Margins

  • IDD has a Gross Margin (49.52%) which is comparable to the rest of the industry.
  • IDD's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for IDD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 49.52%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.49%
GM growth 5Y-4.49%
IDD.DE Yearly Profit, Operating, Gross MarginsIDD.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. IDD.DE Health Analysis

2.1 Basic Checks

  • IDD does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for IDD has been increased compared to 1 year ago.
  • The number of shares outstanding for IDD has been increased compared to 5 years ago.
  • IDD has a better debt/assets ratio than last year.
IDD.DE Yearly Shares OutstandingIDD.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
IDD.DE Yearly Total Debt VS Total AssetsIDD.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • Based on the Altman-Z score of -6.70, we must say that IDD is in the distress zone and has some risk of bankruptcy.
  • IDD's Altman-Z score of -6.70 is on the low side compared to the rest of the industry. IDD is outperformed by 78.48% of its industry peers.
  • A Debt/Equity ratio of 3.52 is on the high side and indicates that IDD has dependencies on debt financing.
  • With a Debt to Equity ratio value of 3.52, IDD is not doing good in the industry: 63.29% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 3.52
Debt/FCF N/A
Altman-Z -6.7
ROIC/WACCN/A
WACC6.4%
IDD.DE Yearly LT Debt VS Equity VS FCFIDD.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

  • IDD has a Current Ratio of 2.21. This indicates that IDD is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of IDD (2.21) is comparable to the rest of the industry.
  • A Quick Ratio of 2.21 indicates that IDD has no problem at all paying its short term obligations.
  • The Quick ratio of IDD (2.21) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.21
Quick Ratio 2.21
IDD.DE Yearly Current Assets VS Current LiabilitesIDD.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. IDD.DE Growth Analysis

3.1 Past

  • IDD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -30.42%.
  • Looking at the last year, IDD shows a very negative growth in Revenue. The Revenue has decreased by -75.86% in the last year.
  • The Revenue for IDD have been decreasing by -28.80% on average. This is quite bad
EPS 1Y (TTM)-30.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.82%
Revenue 1Y (TTM)-75.86%
Revenue growth 3Y1.38%
Revenue growth 5Y-28.8%
Sales Q2Q%-79.85%

3.2 Future

  • IDD is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -19.15% yearly.
  • Based on estimates for the next years, IDD will show a very strong growth in Revenue. The Revenue will grow by 38.93% on average per year.
EPS Next Y-35.8%
EPS Next 2Y-10.55%
EPS Next 3Y-19.15%
EPS Next 5YN/A
Revenue Next Year-26.21%
Revenue Next 2Y3.05%
Revenue Next 3Y2.41%
Revenue Next 5Y38.93%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IDD.DE Yearly Revenue VS EstimatesIDD.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M
IDD.DE Yearly EPS VS EstimatesIDD.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -0.2 -0.4 -0.6

More info and screens

Find the best growth stocksShow best growing peers

0

4. IDD.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for IDD. In the last year negative earnings were reported.
  • Also next year IDD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IDD.DE Price Earnings VS Forward Price EarningsIDD.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IDD.DE Per share dataIDD.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4

4.3 Compensation for Growth

  • IDD's earnings are expected to decrease with -19.15% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.55%
EPS Next 3Y-19.15%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IDD.DE Dividend Analysis

5.1 Amount

  • IDD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IDD.DE Fundamentals: All Metrics, Ratios and Statistics

INNATE PHARMA SA

FRA:IDD (3/20/2026, 7:00:00 PM)

1.086

-0.42 (-27.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-26
Inst Owners9.46%
Inst Owner ChangeN/A
Ins Owners0.92%
Ins Owner ChangeN/A
Market Cap101.76M
Revenue(TTM)6.00M
Net Income(TTM)-46.05M
Analysts80
Price Target5.58 (413.81%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-2.23%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 16.96
P/FCF N/A
P/OCF N/A
P/B 19.78
P/tB 19.78
EV/EBITDA N/A
EPS(TTM)-0.55
EYN/A
EPS(NY)-0.5
Fwd EYN/A
FCF(TTM)-0.44
FCFYN/A
OCF(TTM)-0.44
OCFYN/A
SpS0.06
BVpS0.05
TBVpS0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -49.55%
ROE -895.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 49.52%
FCFM N/A
ROA(3y)-25.54%
ROA(5y)-23.43%
ROE(3y)-227.3%
ROE(5y)-154.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.49%
GM growth 5Y-4.49%
F-Score2
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 3.52
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.84%
Cap/Sales 2.82%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.21
Quick Ratio 2.21
Altman-Z -6.7
F-Score2
WACC6.4%
ROIC/WACCN/A
Cap/Depr(3y)22.77%
Cap/Depr(5y)23.45%
Cap/Sales(3y)3.3%
Cap/Sales(5y)8.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.82%
EPS Next Y-35.8%
EPS Next 2Y-10.55%
EPS Next 3Y-19.15%
EPS Next 5YN/A
Revenue 1Y (TTM)-75.86%
Revenue growth 3Y1.38%
Revenue growth 5Y-28.8%
Sales Q2Q%-79.85%
Revenue Next Year-26.21%
Revenue Next 2Y3.05%
Revenue Next 3Y2.41%
Revenue Next 5Y38.93%
EBIT growth 1Y-31.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year68.86%
EBIT Next 3Y68.81%
EBIT Next 5YN/A
FCF growth 1Y-27.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.01%
OCF growth 3YN/A
OCF growth 5YN/A

INNATE PHARMA SA / IDD.DE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for INNATE PHARMA SA?

ChartMill assigns a fundamental rating of 2 / 10 to IDD.DE.


Can you provide the valuation status for INNATE PHARMA SA?

ChartMill assigns a valuation rating of 0 / 10 to INNATE PHARMA SA (IDD.DE). This can be considered as Overvalued.


How profitable is INNATE PHARMA SA (IDD.DE) stock?

INNATE PHARMA SA (IDD.DE) has a profitability rating of 0 / 10.


Can you provide the financial health for IDD stock?

The financial health rating of INNATE PHARMA SA (IDD.DE) is 3 / 10.